Investigational drug · Phase 3
HiCM-188 therapy
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Heart Failure.
Phase 3Last checked: Nov 20, 2026Latest source record: May 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "HiCM-188 therapy"
First trial start
2023
Sep 5, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HiCM-188 therapy", any sponsor or status.
Conditions studied
As listed on its trial records.
- Heart Failure
Approved drugs for the same conditions: Heart failure · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "HiCM-188 therapy" as an intervention, largest first.
- A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)Pivotal-lookingRecruiting
HELP Therapeutics Co., Ltd.Industry
NCT07496372 · 80 participants (planned) · Start Apr 30, 2026 · Primary completion Jun 30, 2027
Drug: HiCM-188 therapy · For: Heart Failure
Sites: Tianjin, China
- Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart FailureActive, not recruiting
HELP Therapeutics Co., Ltd.Industry
NCT06340048 · 36 participants (planned) · Start Sep 5, 2023 · Primary completion Nov 10, 2026
Drug: HiCM-188 therapy · For: Heart Failure
Sites: Tianjin, China
HELP Therapeutics Co., Ltd.Industry
NCT07471698 · 16 participants (planned) · Start Oct 20, 2026 · Primary completion Oct 20, 2028
Drug: HiCM-188 Chitosan Patch; Blank Chitosan Patch · For: Ischemic Heart Failure; CABG-patients
Sites: Changsha, China
- HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass SurgeryNot yet recruiting
HELP Therapeutics, Inc.Industry
NCT07646210 · 12 participants (planned) · Start Feb 2027 · Primary completion Feb 2028
Drug: HiCM-188 Cells · For: Advanced Heart Failure; Ischemic Heart Failure
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Heart Failure
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- IRP101meta-fluorobenzylguanidine, 18F-MFBGPhase 34 trials
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Cardiovascular Diseases, Heart Failure, Ischemic Cardiomyopathy
- ZiltivekimabPhase 34 trials
Novo Nordisk · Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure
- Qishen Yiqi Dripping Pills 2 bagsPhase 32 trials
Tasly Pharmaceutical Group Co., Ltd · Heart Failure, Chronic Heart Failure With Preserved Ejection Fraction
- IMR-687Tovinontrine, CRD-750Phase 23 trials
Cardurion Pharmaceuticals, Inc. · Heart Failure, Cardiovascular Diseases, Heart Diseases
- CDR132LPhase 22 trials
Novo Nordisk · Heart Failure
- AZD3427Phase 21 trial
AstraZeneca · Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.